Vivos Therapeutics Files 8-K on Financials
Ticker: VVOS · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1716166
| Field | Detail |
|---|---|
| Company | Vivos Therapeutics, Inc. (VVOS) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Vivos Therapeutics dropped an 8-K on financials - check it out!
AI Summary
Vivos Therapeutics, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition as of August 14, 2024. The filing includes financial statements and exhibits, with the company previously known as Vivos BioTechnologies, Inc. before a name change on September 1, 2017.
Why It Matters
This 8-K filing provides an update on Vivos Therapeutics' financial condition and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant negative news.
Key Players & Entities
- Vivos Therapeutics, Inc. (company) — Registrant
- Vivos BioTechnologies, Inc. (company) — Former company name
- August 14, 2024 (date) — Date of earliest event reported
- August 15, 2024 (date) — Filing date
- September 1, 2017 (date) — Date of name change
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on August 14, 2024.
What is the company's principal executive office address?
The address is 7921 Southpark Plaza, Suite 210, Littleton, Colorado 80120.
What was Vivos Therapeutics, Inc. formerly known as?
The company was formerly known as Vivos BioTechnologies, Inc.
When did the company change its name?
The date of the name change was September 1, 2017.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-08-14 18:23:53
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 91KB
- 0001493152-24-032453.txt ( ) — 312KB
- vvos-20240814.xsd (EX-101.SCH) — 3KB
- vvos-20240814_lab.xml (EX-101.LAB) — 33KB
- vvos-20240814_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 7921 Southpark Plaza , Suite 210 Littleton , Colorado 80120 (Address of principal executive offices) (Zip Code) (844) 672-4357 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02. Results of Operations and Financial Condition. On August 14, 2024, Vivos Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated August 14, 2024, announcing its financial results for the second quarter ended June 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIVOS THERAPEUTICS, INC. Dated: August 14, 2024 By: /s/ Bradford Amman Name: Bradford Amman Title: Chief Financial Officer